Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6407)
All Articles published online
|
Publishing Process of This Article
|
Oct 14, 2018 (publication date) through Apr 18, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Schaffner D, Lazaro A, Deibert P, Hasselblatt P, Stoll P, Fauth L, Baumstark MW, Merfort I, Schmitt-Graeff A, Kreisel W. Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension. World J Gastroenterol 2018; 24(38): 4356-4368 [PMID: 30344420 DOI: 10.3748/wjg.v24.i38.4356] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v24/i38/4356.htm |
| Number | Citing Articles |
| 1 |
Adhara Lazaro, Patrick Stoll, Dominik von Elverfeldt, Wolfgang Kreisel, Peter Deibert. Close Relationship between Systemic Arterial and Portal Venous Pressure in an Animal Model with Healthy Liver. International Journal of Molecular Sciences 2023; 24(12): 9963 doi: 10.3390/ijms24129963
|
| 2 |
Robert Schierwagen, Sabine Klein, Frank Uschner, Jonel Trebicka. Novel Targets and Drug Development in Portal Hypertension. Current Hepatology Reports 2019; 18(2): 187 doi: 10.1007/s11901-019-00462-4
|
| 3 |
Ksenia Brusilovskaya, Philipp Königshofer, Daniel Lampach, Adrian Szodl, Paul Supper, David Bauer, Andrea Beer, Judith Stift, Gerald Timelthaler, Georg Oberhuber, Bruno Karl Podesser, Martha Seif, Kerstin Zinober, Nataliya Rohr‐Udilova, Michael Trauner, Thomas Reiberger, Philipp Schwabl. Soluble guanylyl cyclase stimulation and phosphodiesterase‐5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct–ligated rats. United European Gastroenterology Journal 2020; 8(10): 1174 doi: 10.1177/2050640620944140
|
| 4 |
Lukas Sturm, Dominik Bettinger, Lisa Roth, Katharina Zoldan, Laura Stolz, Chiara Gahm, Jan Patrick Huber, Marlene Reincke, Rafael Kaeser, Tobias Boettler, Wolfgang Kreisel, Robert Thimme, Michael Schultheiss. Plasma Cyclic Guanosine Monophosphate Is a Promising Biomarker of Clinically Significant Portal Hypertension in Patients With Liver Cirrhosis. Frontiers in Medicine 2022; 8 doi: 10.3389/fmed.2021.803119
|
| 5 |
Amanda K. Jones, Hongxing Chen, Khing Jow Ng, Jorge Villalona, Mark McHugh, Svetlana Zeveleva, James Wilks, Klaus Brilisauer, Tom Bretschneider, Hu Sheng Qian, Ryan M. Fryer. Soluble Guanylyl Cyclase Activator BI 685509 Reduces Portal Hypertension and Portosystemic Shunting in a Rat Thioacetamide-Induced Cirrhosis Model. Journal of Pharmacology and Experimental Therapeutics 2023; 386(1): 70 doi: 10.1124/jpet.122.001532
|
| 6 |
Eric J. Lawitz, Thomas Reiberger, Jörn M. Schattenberg, Corinna Schoelch, Harvey O. Coxson, Diane Wong, Judith Ertle. Safety and pharmacokinetics of BI 685509, a soluble guanylyl cyclase activator, in patients with cirrhosis: A randomized Phase Ib study. Hepatology Communications 2023; 7(11) doi: 10.1097/HC9.0000000000000276
|
| 7 |
Eric Felli, Yelidousi Nulan, Sonia Selicean, Cong Wang, Jordi Gracia-Sancho, Jaume Bosch. Emerging Therapeutic Targets for Portal Hypertension. Current Hepatology Reports 2023; 22(1): 51 doi: 10.1007/s11901-023-00598-4
|
| 8 |
Wolfgang Kreisel, Adhara Lazaro, Jonel Trebicka, Markus Grosse Perdekamp, Annette Schmitt-Graeff, Peter Deibert. Cyclic GMP in Liver Cirrhosis—Role in Pathophysiology of Portal Hypertension and Therapeutic Implications. International Journal of Molecular Sciences 2021; 22(19): 10372 doi: 10.3390/ijms221910372
|
| 9 |
Susana G. Rodrigues, Yuly P. Mendoza, Jaime Bosch. Investigational drugs in early clinical development for portal hypertension. Expert Opinion on Investigational Drugs 2022; 31(8): 825 doi: 10.1080/13543784.2022.2095259
|
| 10 |
Ji-Yao Sheng, Zi-Fan Meng, Qiao Li, Yong-Sheng Yang. Recent advances in promising drugs for primary prevention of gastroesophageal variceal bleeding with cirrhotic portal hypertension. Hepatobiliary & Pancreatic Diseases International 2024; 23(1): 4 doi: 10.1016/j.hbpd.2023.08.003
|
| 11 |
Frank E. Uschner, Kathleen Glückert, Rafael Paternostro, Thorsten Gnad, Robert Schierwagen, Mattias Mandorfer, Fernando Magdaleno, Cristina Ortiz, Katharina Schwarzkopf, Patrick S. Kamath, Carlo Alessandria, Christoph Boesecke, Alexander Pfeifer, Thomas Reiberger, Wolfgang Kreisel, Tilman Sauerbruch, Arnulf Ferlitsch, Jonel Trebicka, Sabine Klein. Combination of phosphodiesterase‐5‐inhibitors and beta blockers improves experimental portal hypertension and erectile dysfunction. Liver International 2020; 40(9): 2228 doi: 10.1111/liv.14586
|
| 12 |
Yasuko Iwakiri, Jonel Trebicka. Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy. JHEP Reports 2021; 3(4): 100316 doi: 10.1016/j.jhepr.2021.100316
|
| 13 |
Noureen Zahra, Shazia Rafique, Zoya Naveed, Jannat Nadeem, Muhammad Waqas, Amjad Ali, Masaud Shah, Muhammad Idrees. Regulatory pathways and therapeutic potential of PDE4 in liver pathophysiology. Life Sciences 2024; 345: 122565 doi: 10.1016/j.lfs.2024.122565
|
| 14 |
Hui Li. Intercellular crosstalk of liver sinusoidal endothelial cells in liver fibrosis, cirrhosis and hepatocellular carcinoma. Digestive and Liver Disease 2022; 54(5): 598 doi: 10.1016/j.dld.2021.07.006
|
| 15 |
Wolfgang Kreisel, Denise Schaffner, Adhara Lazaro, Jonel Trebicka, Irmgard Merfort, Annette Schmitt-Graeff, Peter Deibert. Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension. International Journal of Molecular Sciences 2020; 21(17): 6223 doi: 10.3390/ijms21176223
|